It was found that when standard chemotherapy is combined with lapatinib regimens, which simultaneously block ErbB1 and 2 receptors, pancreatic cancer cell growth and proliferation are decreased, and apoptotic cell death is promoted [27]. Here, EGFR is linked to familial pancreatic carcinoma.